Optimal Everolimus Concentration Is Associated With Risk Reduction for Acute Rejection in De Novo Renal Transplant Recipients
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Transplantation
Reference19 articles.
1. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.;Vítko;Transplantation,2004
2. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.;Vítko;Am J Transplant,2005
3. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study.;Lorber;Transplantation,2005
4. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.;Lorber;Clin Transplant,2005
5. Everolimus and reduced- exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study.;Nashan;Transplantation,2004
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients;International Journal of Molecular Sciences;2022-10-03
2. Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients;Transplant Immunology;2022-08
3. Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles;CPT: Pharmacometrics & Systems Pharmacology;2022-05-22
4. What Therapeutic Regimen Will Be Optimal for Initial Clinical Trials of Pig Organ Transplantation?;Transplantation;2021-01-27
5. Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1;Pharmacological Reports;2020-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3